Compare Stocks: TLSA, ATOS, ETON, and FSDC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.23 -5.9%	$2.43	$1.70 ▼ $14.85	$23.65M	1.27	98,433 shs	68,006 shs
ETON Eton Pharmaceuticals	$53.67 +3.6%	$56.16	$14.27 ▼ $66.37	$1.48B	0.9	496,225 shs	369,212 shs
FSDC FS Development	$66.85 +1.6%	$13.90	$9.80 ▼ $13.75	$836.70M	N/A	332,704 shs	415,625 shs
TLSA Tiziana Life Sciences	$0.90 -4.8%	$1.01	$0.76 ▼ $1.96	$120.90M	0.45	519,528 shs	187,633 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-0.42%	-6.32%	+20.92%	+8.22%	-83.11%
ETON Eton Pharmaceuticals	+1.25%	+5.07%	-12.47%	+5.65%	+178.49%
FSDC FS Development	0.00%	0.00%	0.00%	0.00%	-25.43%
TLSA Tiziana Life Sciences	+8.94%	-5.94%	-3.11%	-2.06%	-51.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.23 -5.9%	$2.43	$1.70 ▼ $14.85	$23.65M	1.27	98,433 shs	68,006 shs
ETON Eton Pharmaceuticals	$53.67 +3.6%	$56.16	$14.27 ▼ $66.37	$1.48B	0.9	496,225 shs	369,212 shs
FSDC FS Development	$66.85 +1.6%	$13.90	$9.80 ▼ $13.75	$836.70M	N/A	332,704 shs	415,625 shs
TLSA Tiziana Life Sciences	$0.90 -4.8%	$1.01	$0.76 ▼ $1.96	$120.90M	0.45	519,528 shs	187,633 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-0.42%	-6.32%	+20.92%	+8.22%	-83.11%
ETON Eton Pharmaceuticals	+1.25%	+5.07%	-12.47%	+5.65%	+178.49%
FSDC FS Development	0.00%	0.00%	0.00%	0.00%	-25.43%
TLSA Tiziana Life Sciences	+8.94%	-5.94%	-3.11%	-2.06%	-51.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.50	Moderate Buy	$20.33	811.81% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$71.50	33.22% Upside
FSDC FS Development	0.00	N/A	N/A	N/A
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, ATOS, ETON, and FSDC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/15/2026	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$78.00
10/14/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$70.00
10/12/2026	ETON Eton Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
9/22/2026	ETON Eton Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Hold (C)
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/24/2026	ETON Eton Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/14/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$60.00 ➝ $68.00

(Data available from 10/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ETON Eton Pharmaceuticals	$79.95M	19.19	$0.01 per share	9,993.83	$0.98 per share	54.77
FSDC FS Development	N/A	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
ETON Eton Pharmaceuticals	-$4.60M	$0.38	141.24	27.66	N/A	12.02%	40.13%	12.37%	11/5/2026 (Estimated)
FSDC FS Development	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TLSA, ATOS, ETON, and FSDC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ATOS Atossa Genetics	-$0.86	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	ETON Eton Pharmaceuticals	$0.3125	N/A	N/A	N/A	$41.99 million	N/A
8/13/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.1898	$0.43	+$0.2402	$0.35	$27.11 million	$37.59 million
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FSDC FS Development	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	5.69	5.69
ETON Eton Pharmaceuticals	0.41	1.52	1.30
FSDC FS Development	N/A	2.91	2.91
TLSA Tiziana Life Sciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ETON Eton Pharmaceuticals	27.86%
FSDC FS Development	89.82%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
ETON Eton Pharmaceuticals	16.49%
FSDC FS Development	N/A
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
ETON Eton Pharmaceuticals	44	28.58 million	23.87 million	Optionable
FSDC FS Development	N/A	12.52 million	N/A	Not Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

TLSA, ATOS, ETON, and FSDC Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Stock Lifted to "Sell" by Wall Street Zen

October 24, 2026 | americanbankingnews.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Raised to Sell at Wall Street Zen

October 24, 2026 | marketbeat.com

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

October 21, 2026 | markets.businessinsider.com

Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2026

October 17, 2026 | marketscreener.comM

Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Intranasal Foralumab in Alzheimer's Disease

October 16, 2026 | finance.yahoo.com

Tiziana Completes Enrollment And Dosing In Phase 2 Alzheimer's Study Of Intranasal Foralumab

October 16, 2026 | rttnews.com

Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

October 16, 2026 | finance.yahoo.com

Tiziana Life Sciences, Ltd. Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer?S Disease

October 16, 2026 | marketscreener.comM

Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab

October 16, 2026 | proactiveinvestors.com

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease

October 16, 2026 | globenewswire.com

Tiziana Life Sciences (TLSA) Gets a Buy from BTIG

October 7, 2026 | theglobeandmail.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Lowered by Wall Street Zen

October 3, 2026 | marketbeat.com

Tiziana Files For Orphan Drug Designation For Foralumab In MSA

September 30, 2026 | rttnews.com

Tiziana Seeks FDA Orphan Drug Designation For Intranasal Foralumab

September 30, 2026 | rttnews.com

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

September 30, 2026 | proactiveinvestors.com

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

September 30, 2026 | finance.yahoo.com

Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial

September 30, 2026 | finance.yahoo.com

Tiziana Life Sciences, Ltd. Announces First Participants Dosed In ALS BANYAN Clinical Trial Of Intranasal Foralumab

September 29, 2026 | marketscreener.comM

Tiziana Begins Phase 2a BANYAN Trial Of Intranasal Foralumab In ALS Patients

September 28, 2026 | rttnews.com

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

September 28, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

September 28, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TLSA, ATOS, ETON, and FSDC Company Descriptions

Atossa Genetics NASDAQ:ATOS

$2.23 -0.14 (-5.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.22 0.00 (-0.22%)

As of 07:30 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Eton Pharmaceuticals NASDAQ:ETON

$53.67 +1.87 (+3.61%)

Closing price 04:00 PM Eastern

Extended Trading

$53.14 -0.53 (-0.99%)

As of 07:30 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

FS Development NASDAQ:FSDC

FS Development Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was founded in 2020 and is based in San Francisco, California.

Tiziana Life Sciences NASDAQ:TLSA

$0.90 -0.05 (-4.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 +0.03 (+2.80%)

As of 07:30 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, ATOS, ETON, and FSDC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, ATOS, ETON, and FSDC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, ATOS, ETON, and FSDC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TLSA, ATOS, ETON, and FSDC Company Descriptions

Atossa Genetics NASDAQ:ATOS

Eton Pharmaceuticals NASDAQ:ETON

FS Development NASDAQ:FSDC

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, ATOS, ETON, and FSDC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, ATOS, ETON, and FSDC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, ATOS, ETON, and FSDC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TLSA, ATOS, ETON, and FSDC Company Descriptions

Atossa Genetics NASDAQ:ATOS

Eton Pharmaceuticals NASDAQ:ETON

FS Development NASDAQ:FSDC

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools